Vitamin D deficiency may predict aggressive prostate cancer

Past research has associated low levels of vitamin D with a number of health problems. Now, a new study published in the journal Clinical Cancer Research suggests that vitamin D deficiency may be an indicator of aggressive prostate cancer.

According to study author Dr. Adam B. Murphy, assistant professor in the Department of Urology at the Northwestern University Feinburg School of Medicine in Chicago, IL, vitamin D is known to impact the growth and differentiation of benign and malignant prostate cells, both in prostate cell lines and animal models of prostate cancer.

However, their study revealed that low levels of the vitamin in men appeared to predict the risk of aggressive prostate cancer.

To reach their findings, the team enrolled 275 European-American men and 273 African-American men to the study between 2009 and 2013.

The men were aged between 40 and 79 years and were undergoing an initial prostate biopsy after abnormal prostate-specific antigen (PSA) or digital rectal examination (DRE) test results. A prostate cancer diagnosis from their biopsy was given to 168 men from each group.

In order to determine the levels of vitamin D in the men, the researchers measured levels of 25-hydroxyvitamin D (25-OH D) in their blood. The normal range of 25-OH D is 30 to 80 nanograms per milliliter (ng/ml).

The lower the vitamin D levels, the higher the risk of aggressive prostate cancer

The team found that the mean 25-OH D levels of African-American men were much lower than that of European-American men, at 16.7 ng/ml and 19.3 ng/ml, respectively.

The highest 25-OH D level found in European-American men was 71 ng/ml, while the highest level found in African-American men was only 45 ng/ml.

The researchers then divided the men into groups dependent on their 25-OH D levels. They were:

Less than 12 ng/ml Less than 16 ng/ml Less than 20 ng/ml Less than 30 ng/ml.

They found that the lower a man's vitamin D levels, the higher their risk of prostate cancer.

With 25-OH D levels lower than 12 ng/ml, European-American men were 3.66 times more likely to develop aggressive prostate cancer (Gleason grade 4+4 or higher), while African-American men were 4.89 times more likely to develop an aggressive form of the disease.

European-American men were also 2.42 times more likely to have a stage T2b tumor (when cancer can be felt or seen on scans but is contained within the prostate) if 25-OH D were less than 12 ng/ml, while African-American men were 4.22 times more likely to have a stage T2b tumor.

Furthermore, the researchers found that African-American men were also 2.43 times more likely to be diagnosed with prostate cancer if their 25-OH D levels were less than 20 ng/ml. No association was found between vitamin D deficiency and increased risk of prostate cancer diagnosis in European-American men.